Free Trial

Korro Bio (KRRO) 10K Form and Latest SEC Filings 2026

Korro Bio logo
$9.97 -0.21 (-2.06%)
Closing price 04:00 PM Eastern
Extended Trading
$9.95 -0.02 (-0.20%)
As of 05:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Korro Bio SEC Filings & Recent Activity

Korro Bio (NASDAQ:KRRO) has submitted 542+ documents to the U.S. Securities and Exchange Commission (SEC) since 2019. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 424B3 submitted on May 12, 2026.

Form 4
Korro Bio, Inc. Reports Ownership Change on Apr. 2, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Korro Bio Files Current Report on May. 7, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Korro Bio Files Quarterly Report on May. 7, 2026

The 10-Q contains Korro Bio's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Korro Bio SEC Filing History

Browse Korro Bio's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/12/2026 3:49 PM
Korro Bio (1703647) Filer
Form 424B3
05/07/2026 6:08 AM
Korro Bio (1703647) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/07/2026 6:04 AM
Korro Bio (1703647) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/16/2026 6:10 AM
Korro Bio (1703647) Filer
Form ARS
04/16/2026 6:00 AM
Korro Bio (1703647) Filer
Form DEF 14A
04/16/2026 6:05 AM
Korro Bio (1703647) Filer
Form DEFA14A
04/02/2026 11:00 AM
Korro Bio (1703647) Issuer
Lynx1 Capital Management LP (1910456) Reporting
Nichols Weston (1746376) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/02/2026 11:00 AM
Korro Bio (1703647) Issuer
Lynx1 Capital Management LP (1910456) Reporting
Nichols Weston (1746376) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2026 11:01 AM
Korro Bio (1703647) Subject
Lynx1 Capital Management LP (1910456) Filed by
Form SCHEDULE 13G/A
03/22/2026 11:15 PM
Korro Bio (1703647) Filer
Form EFFECT
03/20/2026 4:03 PM
Korro Bio (1703647) Filer
Form 424B5
03/13/2026 4:05 PM
Korro Bio (1703647) Filer
Form S-3
Registration statement under Securities Act of 1933  
03/12/2026 7:15 PM
Florence Anthony A. Jr. (1559827) Reporting
Korro Bio (1703647) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2026 7:15 PM
Korro Bio (1703647) Issuer
Walker Paul Edward (1553150) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2026 7:15 PM
Korro Bio (1703647) Issuer
Makhzoumi Mohamad (1630226) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2026 7:15 PM
Korro Bio (1703647) Issuer
Mathers Edward T (1328625) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2026 7:15 PM
BASKETT FOREST (1277631) Reporting
Korro Bio (1703647) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2026 7:15 PM
Behbahani Ali (1613867) Reporting
Korro Bio (1703647) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2026 7:15 PM
Chang Carmen (1746342) Reporting
Korro Bio (1703647) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2026 7:15 PM
Korro Bio (1703647) Issuer
NEA 17 GP, LLC (1796821) Reporting
NEA Partners 17, L.P. (1796820) Reporting
New Enterprise Associates 17, L.P. (1768564) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2026 7:15 PM
Korro Bio (1703647) Issuer
SANDELL SCOTT D (1237289) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2026 7:15 PM
Korro Bio (1703647) Issuer
Yang Rick (1851328) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2026 6:32 PM
Korro Bio (1703647) Subject
New Enterprise Associates 17, L.P. (1768564) Filed by
Form SCHEDULE 13D/A
03/11/2026 4:24 PM
Korro Bio (1703647) Subject
Form SCHEDULE 13G
03/11/2026 4:24 PM
Korro Bio (1703647) Subject
Point72 Asset Management, L.P. (1603466) Filed by
Point72 Asset Management, L.P. (1603466) Filed by
Form SCHEDULE 13G
03/09/2026 6:35 AM
Korro Bio (1703647) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/17/2026 3:29 PM
Korro Bio (1703647) Subject
Point72 Asset Management, L.P. (1603466) Filed by
Form SCHEDULE 13G/A
02/17/2026 8:07 AM
DRIEHAUS CAPITAL MANAGEMENT LLC (938206) Filed by
Korro Bio (1703647) Subject
Form SCHEDULE 13G/A
02/03/2026 3:17 PM
Aiyar Ram (1997920) Reporting
Korro Bio (1703647) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/30/2026 2:25 PM
Korro Bio (1703647) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G
01/27/2026 8:15 AM
Korro Bio (1703647) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/15/2026 3:05 PM
Korro Bio (1703647) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/05/2026 4:40 PM
Korro Bio (1703647) Subject
Lynx1 Capital Management LP (1910456) Filed by
Form SCHEDULE 13G
12/16/2025 3:05 PM
Dolan Oliver (2053835) Reporting
Korro Bio (1703647) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 3:07 PM
Cerio Jeffrey (2033618) Reporting
Korro Bio (1703647) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2025 7:52 AM
DRIEHAUS CAPITAL MANAGEMENT LLC (938206) Filed by
Korro Bio (1703647) Subject
Form SCHEDULE 13G/A
11/12/2025 3:08 PM
Korro Bio (1703647) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/12/2025 3:09 PM
Korro Bio (1703647) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/08/2025 6:30 AM
Korro Bio (1703647) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/14/2025 7:47 AM
Deep Track Capital, LP (1856083) Filed by
Korro Bio (1703647) Subject
Form SCHEDULE 13G/A
08/13/2025 2:50 PM
ALLIANCEBERNSTEIN L.P. (1109448) Filed by
Korro Bio (1703647) Subject
Form SCHEDULE 13G/A
Your $29.97 book is free today (Ad)

Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel

Normally $29.97. Today it's free. Grab your copy now.
08/12/2025 6:10 AM
Korro Bio (1703647) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/12/2025 6:05 AM
Korro Bio (1703647) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/12/2025 3:32 PM
Korro Bio (1703647) Issuer
Meyers Rachel (2001472) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)

Korro Bio SEC Filings - Frequently Asked Questions

Korro Bio (KRRO) has submitted 542+ filings to the SEC since 2019. You can browse the complete history or filter by form type using the tools above.

Korro Bio's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form 424B3 submitted on May 12, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:KRRO) was last updated on 5/18/2026 by MarketBeat.com Staff.
From Our Partners